Position in VYGR
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$263,014
-$26,169 QoQ
Shares Held
75,147
+0.3% QoQ
Ownership
0.122%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#48
of 135 holders
Holding Since
Mar 2020
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in VYGR Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Birchview Capital, LP holds $91,246,272 across 49 Biotechnology names. VYGR ranks #44 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SLDB |
Solid Biosciences Inc.
|
666,196 | $6,655,298 | |
| 2 | NTLA |
Intellia Therapeutics, Inc.
|
385,900 | $6,529,428 | |
| 3 | STOK |
Stoke Therapeutics, Inc.
|
178,110 | $5,827,759 | |
| 4 | NKTR |
Nektar Therapeutics
|
81,000 | $5,654,610 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
57,200 | $4,973,540 | |
| 6 | PRTA |
Prothena Corp Public Ltd Co
|
449,019 | $4,395,896 | |
| 7 | ACAD |
Acadia Pharmaceuticals Inc
|
171,000 | $4,326,300 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
35,018 | $4,292,506 |
All Filings in VYGR
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $263,014 | 75,147 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $289,183 | 74,918 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $294,427 | 74,918 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $630,067 | 134,918 | Shares | Sole | 2025-11-13 | |
| 2020-09-30 | $320,100 | 30,000 | Shares | Sole | 2020-11-12 | |
| 2020-06-30 | $378,600 | 30,000 | Shares | Sole | 2020-09-25 | |
| 2020-03-31 | $274,500 | 30,000 | Shares | Sole | 2020-05-12 | |
| No filing history on record for this holder in this stock. | ||||||